Pipeline

We are utilizing our technology platforms to develop product candidates for immune disorders, cancer and haematological diseases.

We are developing therapeutics designed to modulate the immune system, to overcome cancer immune tolerance and escape. We are also developing therapeutics designed to treat autoimmune diseases.

Amlitelimab SAR445229 (formerly KY1005), Alomfilimab SAR445256 (formerly KY1044) and KY1043 are designed to balance the activation and suppression of the immune system to treat disease.